目的:探讨脑钠肽(BNP)和 N末端B型利钠肽前体(NT-proBNP)对急性呼吸窘迫综合征患者诊断中的意义以及对治疗的指导作用。方法:对124例有明确器质性心脏病或者突发呼吸窘迫患者(检测组)进行 BNP和NT-proBNP检查,判断心衰与否。另选110例发生急性呼吸窘迫但未做BNP、NT-proBNP检查的患者作为未检测对照组,收集所有患者诊断时间、住院时间、住院费用、死亡率等相关资料。结果:与未检测对照组比较,检测组诊断时间[(24.2±6.4)min比(16.3±5.2)min]、住院时间显著缩短[(12.5±3.5)d比(8.5±4.5)d],死亡率显著降低(8.18%比4.84%),P均<0.05;两组平均住院费用无明显差异(P>0.05)。结论:脑钠肽和N末端B型利钠肽前体的检测对于早期诊断急性呼吸窘迫综合征,提高疗效和改善预后有重要价值。
Objective:To explore significance of brain natriuretic peptide (BNP)and N terminal pro brain natriuretic peptide (NT-proBNP)for diagnosis of acute respiratory distress syndrome and its guidance of treatment.Methods:A total of 124 cases with definite organic heart disease and sudden respiratory distress syndrome (measurement group) received measurement of BNP and NT-proBNP to judge whether they suffered from heart failure or not.Another 110 patients with acute respiratory distress syndrome but no receiving BNP and NT-proBNP measurement were en-rolled as no measurement control group.Relevant data,including diagnosis time,length of hospital stay,hospitali-zation cost and mortality rate etc,were collected in all patients.Results:Compared with no measurement control group,there were significant reductions in diagnosis time [(24.2±6.4)min vs.(16.3±5.2)min],length of hospi-tal stay [(12.5±3.5)d vs.(8.5±4.5)d]and mortality rate (8.18% vs.4.84%)in measurement group,P<0.05 all;there was no significant difference in mean hospitalization cost between two groups (P>0.05).Conclusion:Measurement of brain natriuretic peptide and N terminal pro brain natriuretic peptide possesses important value for early diagnosis,elevating therapeutic effect and improving prognosis in patients with acute respiratory distress syn-drome.